Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 30, 2023

Primary Completion Date

May 30, 2026

Study Completion Date

October 30, 2026

Conditions
Primary AldosteronismPrimary Aldosteronism Due to Aldosterone Producing Adenoma
Interventions
COMBINATION_PRODUCT

Al18F-NOTA-Pentixafor PET/CT

"Participants will receive an intravenous injection of Al18F-NOTA-Pentixafor, prepared on-site and measured by qualified personnel using a dose calibrator, with readings and time recorded. The radiopharmaceutical will be slowly administered through a three-way stopcock, followed by a flush with 5 mL of normal saline.~The recommended dose is approximately 4.81 MBq/kg (0.13 mCi/kg) body weight, with variations depending on drug yield and clinical scheduling.~CT and PET imaging are planned 45-90 minutes after administration, with adjustments based on drug yield and equipment availability."

Trial Locations (1)

Unknown

RECRUITING

Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER